FDA OKs Lilly's Dog-Anxiety Drug
Posted on: Wednesday, 25 April 2007, 12:00 CDT
Eli Lilly said Wednesday the U.S. Food and Drug Administration approved Reconcile for treatment of separation anxiety in dogs.
Reconcile -- which has the same active ingredient as Prozac -- is a selective serotonin reuptake inhibitor antidepressant. The chewable, flavored tablet is now available to U.S. veterinarians.
Lilly research shows that 10.7 million, or up to 17 percent of U.S. dogs suffer from separation anxiety, said Steve Connell, Lilly's manager of technical, academic and consumer services for companion animal health. We're thrilled that our first product for dogs can help restore the human-pet bond, which can be compromised when dogs suffer from separation anxiety.
The approval is supported by field studies involving approximately 600 dogs that found that 73 percent of dogs receiving Reconcile showed improvement in separation anxiety-related behavior compared to those receiving behavior training alone.
The most common adverse effects included lethargy, vomiting, shaking, diarrhea, excessive vocalization, aggression and seizures.
Source: United Press International
Related Articles
- How Does Your Pet Deal with the Stress of Summer?
- Ingram Micro Reports First Quarter 2009 Results
- Ingram Micro Reports Fourth-Quarter and Full-Year 2008 Results
- Lockheed Martin Announces 2008 Fourth Quarter and Year-End Results
- Prozac for Pets Can Be Useful but on a Short Leash
- Lilly Plans to Submit Cymbalta(R) (Duloxetine Hydrochloride) New Drug Application for Generalized Anxiety Disorder
- New Jersey Puts Vets on Alert for Canine Flu
- See Cat's Vet Yearly for Best Advice on Vaccines
- New Study Shows People and Pets Can Succeed Together in Fighting The Obesity Epidemic
 |
 |
User Comments (0)
RSS Feeds